MaxCyte, Inc. Grant of Options (4895P)
February 17 2021 - 11:44AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 4895P
MaxCyte, Inc.
17 February 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Gaithersburg, Maryland - 17 February 2021: MaxCyte (LSE: MXCT,
MXCL, MXCN), the global clinical-stage cell-based therapies and
life sciences company, announces that on 16 February 2021, a total
of 729,200 options of common stock in the Company ("Common Stock")
were granted to PDMRs who are directors or officers of the Company
("Option Grants"). Details of the Option Grants are given
below:
Option Grants to PDMRs
Doerfler, Doug 390,200
--------
Holtz, Ron 177,600
--------
Thompson, J. Stark 26,900
--------
Mandell, Art 26,900
--------
Erck, Stan 26,900
--------
Brooke, Will 26,900
--------
Johnston, John 26,900
--------
Douglas, Richard 26,900
--------
Total 729,200
--------
In the case of the Executive Directors and other employees,
Option Grants vest 12/48th of the total grant one year after date
of grant, and thereafter vest 1/48(th) per month for 36 months
after the date of grant. Option Grants for Non-Executive Directors
fully vest at the end of twelve (12) months after date of grant.
The Option Grants have an exercise price of GBP10.40 equal to the
closing price of Maxcyte's stock on 16 February 2021.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Doerfler, Doug
Holtz, Ron
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
Douglas, Richard
================================================================ ===============================================
2 Reason for the notification
=================================================================================================================
a) Position/status Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Thompson, J. Stark - Non-executive Chairman
Mandell, Art - Non-executive Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive Director
Johnston, John - Non-executive Director
Douglas, Richard - Non-executive Director
================================================================ ===============================================
b) Initial notification/Amendment Initial notification
================================================================ ===============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=================================================================================================================
a) Name MaxCyte, Inc.
================================================================ ===============================================
b) LEI 54930053YHXULRFCU991
================================================================ ===============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=================================================================================================================
a) Description of Grant of Options over Shares of Common
the financial instrument, Stock
type of instrument
================================================================ ===============================================
b) Identification US57777K1060
Code
================================================================ ===============================================
c) Nature of the transaction Exercise of options and Sale of Common
Stock by PDMR
================================================================ ===============================================
d) Price(s) and volume(s) Doerfler, Doug - 390,200 at an exercise
price of GBP10.40
Holtz, Ron - 177,600 at an exercise price
of GBP10.40
Thompson, J. Stark - 26,900 at an exercise
price of GBP10.40
Mandell, Art - 26,900 at an exercise
price of GBP10.40
Erck, Stan - 26,900 at an exercise price
of GBP10.40
Brooke, Will - 26,900 at an exercise
price of GBP10.40
Johnston, John - 26,900 at an exercise
price of GBP10.40
Douglas, Richard - 26,900 at an exercise
price of GBP10.40
================================================================ ===============================================
e) Aggregated information N/A
- Aggregated volume N/A
- Price N/A
================================================================ ===============================================
f) Date of the transaction 16 February 2021
================================================================ ===============================================
g) Place of the transaction London Stock Exchange, AIM Market (XLON)
================================================================ ===============================================
About MaxCyte
MaxCyte is a world-leading provider of cell-engineering enabling
technology and is responsible for helping to bring next-generation
cell and gene-editing therapies to life. The Company's technology
is deployed by leading drug developers worldwide, including all of
the top ten global biopharmaceutical companies. MaxCyte licences
have been granted for more than 140 cell therapy programmes, with
more than 100 licensed for clinical use, and the Company has now
entered into twelve clinical/commercial license partnerships with
leading cell therapy and gene editing developers. MaxCyte was
founded in 1998, is listed on the London Stock Exchange (LSE: MXCT,
MXCL, MXCN) and is headquartered in Gaithersburg, Maryland, US. For
more information, visit www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Accounting Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHTRMRTMTBBBIB
(END) Dow Jones Newswires
February 17, 2021 12:44 ET (17:44 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2023 to Apr 2024
